Breaking News

Transgenomic, Amgen in Cancer Detection Pact

May 6, 2013

Will develop test to screen for mCRC

Transgenomic, Inc. has entered into a collaboration with Amgen to develop a CE-IVD test to screen patients with metastatic colorectal cancer (mCRC) for RAS mutations (KRAS and NRAS). These RAS mutations are identified with CE-IVD CRC RAScan kits using Surveyor-Wave technology, and provide physicians with important information regarding tumor mutation status. Financial terms were not disclosed.
 
“This collaboration with Amgen is indicative of how Transgenomic’s proprietary molecular technologies are advancing personalized medicine,” said Craig Tuttle, chief executive officer of Transgenomic. “This highly precise, innovative test was developed at Transgenomic’s laboratories, which excel in genomic and genetic analysis, novel technology development, and its application in clinical research and trials.”

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity